EUVIMEDSkopri EUVIMED
Open access

Modeling Alzheimer's Disease Biomarkers' Trajectory in the Absence of a Gold Standard Using a Bayesian Approach

Wei Jin, Yanxun Xu, Zheyu Wang iD

Statistics in Medicine · 2025

DOI: 10.1002/sim.70283 ↗

At a glance

Journal article in Statistics in Medicine, 2025. Written by Wei Jin and 2 co-authors. Institution: Department of Applied Mathematics and Statistics, Johns Hopkins University, Baltimore, Maryland, USA. Major MEDLINE topics: Alzheimer Disease, Biomarkers, Models, Statistical. Cited 2 times so far (Crossref); 24 references. The full text is freely available in PubMed Central. Funded by: NIA NIH HHS, NIMH NIH HHS, National Institute on Aging.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

To advance our understanding of Alzheimer's Disease (AD), especially during the preclinical stage when patients' brain functions are mostly intact, recent research has shifted towards studying AD biomarkers across the disease continuum. A widely adopted framework in AD research, proposed by Jack and colleagues, maps the progression of these biomarkers from the preclinical stage to symptomatic stages, linking their changes to the underlying pathophysiological processes of the disease. However, most existing studies rely on clinical diagnoses as a proxy for underlying AD status, potentially overlooking early stages of disease progression where biomarker changes occur before clinical symptoms appear. In this work, we develop a novel Bayesian approach to directly model the underlying AD status as a latent disease process and biomarker trajectories as nonlinear functions of disease progression. This allows for more data‐driven exploration of AD progression, reducing potential biases due to inaccurate clinical diagnoses. We address the considerable heterogeneity among individuals' biomarker measurements by introducing a subject‐specific latent disease trajectory as well as incorporating random intercepts to further capture additional inter‐subject differences in biomarker measurements. We evaluate our model's performance through simulation studies. Applications to the Alzheimer's Disease Neuroimaging Initiative (ADNI) study yield interpretable clinical insights, illustrating the potential of our approach in facilitating the understanding of AD biomarker evolution.

Subjects

MeSH terms (MEDLINE)

Alzheimer DiseaseBiomarkersModels, StatisticalHumansBayes TheoremDisease ProgressionComputer SimulationAmyloid beta-Peptides

Author keywords

Alzheimer's DiseaseBayesian nonlinear mixed effects modelbiomarker assessmentdisease predictionlongitudinal data

Substances

BiomarkersAmyloid beta-Peptides

Authors and institutions

  • Department of Applied Mathematics and Statistics, Johns Hopkins University, Baltimore, Maryland, USA.
  • Division of Quantitative Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

ORCID profiles: Zheyu Wang

Funding

  • NIA NIH HHS
  • NIMH NIH HHS
  • National Institute on Aging
  • National Institute of Mental Health

Cite

APA

Jin, W., Xu, Y., & Wang, Z. (2025). Modeling Alzheimer's Disease Biomarkers' Trajectory in the Absence of a Gold Standard Using a Bayesian Approach. Statistics in Medicine. https://doi.org/10.1002/sim.70283

Vancouver

Jin W, Xu Y, Wang Z. Modeling Alzheimer's Disease Biomarkers' Trajectory in the Absence of a Gold Standard Using a Bayesian Approach. Statistics in Medicine. 2025. doi:10.1002/sim.70283

BibTeX
@article{Jin2025,
  author = {Jin, Wei and Xu, Yanxun and Wang, Zheyu},
  title = {Modeling Alzheimer's Disease Biomarkers' Trajectory in the Absence of a Gold Standard Using a Bayesian Approach},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70283}
}
Start for free →